Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod
December 20, 2021 07:00 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 16:30 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021 07:05 ET
|
Checkmate Pharmaceuticals Inc.
Alan Fuhrman appointed interim President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing Clinical data readouts anticipated in 2022 ...
Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 12, 2021 07:01 ET
|
Checkmate Pharmaceuticals Inc.
Vidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1 Vidutolimod also...
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 11, 2021 16:30 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 01, 2021 08:01 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary...
Checkmate Pharmaceuticals Announces CEO Transition
October 27, 2021 16:30 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
October 20, 2021 16:30 ET
|
Checkmate Pharmaceuticals Inc.
Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET Featured speakers include Jason Luke, M.D., FACP and Art Krieg, M.D. CAMBRIDGE,...
Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
September 14, 2021 16:30 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 07:00 ET
|
Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...